GLP-1 and metabolic
How GLP-1, GIP and Glucagon Receptors Differ in Metabolic Research
AM
· 2 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
Quick answer: The headline distinction is one versus two versus three receptor activities, but receptor count alone does not measure clinical effectiveness. Each pathway has different physiological actions, and the engineered molecules vary in their potency and exposure.

The GLP-1 receptor
GLP-1 receptor signalling is involved in glucose-dependent insulin secretion, gastrointestinal physiology and appetite-related pathways. Authorized GLP-1 medicines have clinical trial records specific to their indications and preparations.
The GIP receptor
Glucose-dependent insulinotropic polypeptide is an incretin hormone with insulinotropic effects in appropriate physiological contexts. Dual agonists combine receptor pharmacology in one molecule, not simply two separate drugs mixed in a vial.
The glucagon receptor
Glucagon signalling influences hepatic glucose output and energy metabolism. Co-agonist designs seek to balance multiple actions; this balance is a drug-development question and cannot be read directly from a receptor list.
What receptor labels hide
Binding affinity, intrinsic activity, biased signalling, clearance and exposure all influence biological output. A receptor diagram describes a hypothesis for how the agent works, while randomized trials test benefits and harms in defined populations. Retatrutide remains investigational; do not conflate it with authorized comparators.
Frequently asked questions
Does triple agonist automatically mean strongest? No. Receptor count is not a clinical ranking.
Is tirzepatide simply two peptides combined? No. It is one engineered molecule with activity at two receptor systems.
Supplied here for laboratory use: Tirzepatide and Retatrutide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
Further reading
- GLP-1 Hair Loss: What Tirzepatide Trials Report
- Retatrutide Research: Triple Agonist Explained
- Tirzepatide vs Retatrutide: Research and Regulation
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. pubmed.ncbi.nlm.nih.gov/37366315
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
